Physician name
Name of practice
Street address
City, State, Zip
Dear Colleague:
As a woman’s primary care physician, you play an important role in the early detection of breast cancer by
recommending breast self-examinations and annual mammograms to women in your care.
When early stage breast cancer is detected in one of your patients, you should be aware of a treatment
option that can help women get through their cancer treatments and back to their normal lives sooner.
Name of Practice is pleased to offer MammoSite® 5-Day Targeted Radiation Therapy as a breast
conserving treatment option for patients with early stage breast cancer (see reverse for recommended
guidelines for patient selection). MammoSite Therapy works by delivering radiation from within the
lumpectomy cavity, directly to the tissue surrounding the cavity, where cancer is most likely to recur. 1
MammoSite 5-Day Targeted Radiation Therapy offers patients with early stage breast cancer the
opportunity to complete their radiation treatment in 5 days, as opposed to whole breast radiation therapy
which can take 6 to 7 weeks and can cause many logistical problems for patients, such as juggling work
schedules and arranging for transportation to and from treatments.
Five year follow-up data for MammoSite Therapy has shown the following results:
5-Year Initial Clinical Trial Results (N=43)2
–
–
–
–
No local recurrences.
83.3% of patients had good/excellent cosmetic results.
100% of patients would recommend MammoSite Therapy to a friend or family member.
100% of patients would use MammoSite Therapy if they had to do it over.
We are excited about offering MammoSite 5-Day Targeted Radiation Therapy. We hope you will feel free
to contact us if you should have further questions or if you would like to discuss the appropriateness of this
technique for an early stage breast cancer patient.
Sincerely,
Physician Name, Title
Please see reverse for patient selection criteria.
1
King TA, Bolton JS, Kuske RR, et al. Long-term results of wide-field brachytherapy as the sole method of radiation therapy after
segmental mastectomy for Tis 1, 2 breast cancer. Am J Surg. 2000; 180:299-304.
2
Benitez PR, Keisch ME, Vicini F, et al. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast
irradiation in early-stage breast cancer.Am J Surg. 2007;194:456-462.
© 2009 Hologic Surgical MISC-00569-001 Rev. 001
To determine if a woman is an appropriate candidate for
refer to the guidelines published by the the American Brachytherapy Society,
the American Society of Breast Surgeons, the American College of Radiation
Oncology and the American Society for Radiation Oncology
Professional Medical Society Consensus Guidelines:
Patient Selection Criteria for Accelerated Partial Breast Irradiation
ASTRO4
ABS1
ASBS2
ACRO3
Suitable
Cautionary
>60
50 - 59
Age (yrs)
>50
>45
>45
Diagnosis
Unifocal, invasive
ductal carcinoma
Invasive ductal
carcinoma or ductal
carcinoma in situ
(DCIS)
Invasive ductal
carcinoma or DCIS
Tumor Size
< 3cm
< 3cm
< 3cm
< 2cm
2.1 – 3.0 cm
Surgical
Margins
Negative
microscopic
margins of
excision
Negative microscopic
surgical margins of
excision
Negative microscopic
surgical margins of
excision
Negative by at least
2mm
Close (<2mm)
Nodal Status
NØ
NØ
NØ
NØ (i-,i+)
Invasive ductal or
other favorable
subtypes (ie:
mucinous, tubular,
colloid)
Pure DCIS ≤ 3 cm
EIC ≤ 3 cm
1
M.Keisch, et al. Breast Brachytherapy Task Group, American Brachytherapy Society. February, 2007. http://www.Americanbrachytherapy.org
Consensus statement for accelerated partial breast irradiation. The American Society of Breast Surgeons. December 8, 2005.
3
American College of Radiation Oncology Statement on Partial Breast Irradiation. September, 2008.
4
American Society for Radiation Oncology Consensus Statement on Partial Breast Irradiation. July 2009.
2
Note: ASTRO has issued three categories of patient selection: Suitable indicates appropriate for
treatment outside of a clinical trial; Cautionary indicates that caution and concern should be
exercised at this point in time due to limited data; Unsuitable (not presented above) indicates not
acceptable outside of a clinical trial.
© 2009 Hologic Surgical MISC-00569-001 Rev. 001